Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 18/20 | 1.00 |
| ▸ | DDX5 | P17844 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
| ▸ | HBB | P68871 | 2/20 | 0.75 |
| ▸ | CASP1 | P29466 | 1/20 | 0.75 |
| ▸ | CASP7 | P55210 | 1/20 | 0.75 |
| ▸ | TP53 | P04637 | 2/20 | 0.74 |
| ▸ | GLA | P06280 | 2/20 | 0.74 |
| ▸ | HPGD | P15428 | 2/20 | 0.74 |
| ▸ | STAT6 | P42226 | 1/20 | 0.74 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.74 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.74 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.74 |
| ▸ | GMNN | O75496 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29429769 | 1.00 | TOP1 (1.00) | TOP1DDX5MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20286453 | 1.00 | TOP1 (1.00) | TOP1DDX5MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30255916 | 1.00 | TOP1 (1.00) | TOP1DDX5MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18296600 | 1.00 | TOP1 (1.00) | TOP1DDX5MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9563404 | 1.00 | TOP1 (1.00) | TOP1DDX5MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13931437 | 0.94 | TOP1 (1.00) | TOP1DDX5MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18296599 | 0.94 | TOP1 (1.00) | TOP1DDX5MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25932530 | 0.91 | TOP1 (0.84) | TOP1DDX5MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6786007 | 0.89 | TOP1 (0.80) | TOP1DDX5MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15342071 | 0.89 | TOP1 (0.80) | TOP1DDX5MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384104-B2 | Delivery systems for controlled drug release | CENTURION BIOPHARMA CORPORATION (US) | 2022-07-12 | — | — | US | claimed |
| EP-4748843-A2 | ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2026-05-27 | — | — | EP | disclosed |
| EP-4735598-A2 | NRAS GENE KNOCKOUT FOR TREATMENT OF CANCER | Christiana Care Gene Editing Institute, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260102507-A1 | CAMPTOTHECIN DERIVATIVE FOR TREATING OR PREVENTING CANCER AND ANTIBODY-DRUG CONJUGATE THEREOF | CHENGDU BRILLIANT PHARMACEUTICAL CO LTD (CN) | 2026-04-16 | — | — | US | disclosed |
| US-20250375543-A1 | OLIGONUCLEOTIDE-BASED THERAPEUTICS AND USES THEREOF | SPEER TOD (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250333541-A1 | ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF | EVOPOINT BIOSCIENCES CO LTD (CN) | 2025-10-30 | — | — | US | disclosed |
| EP-4619044-A1 | ANTIBODY-DRUG-CONJUGATES CLEAVABLE IN A TUMOR MICROENVIRONMENT | Lerchen, Hans-Georg (DE) | 2025-09-24 | — | — | EP | disclosed |
| US-12329815-B2 | Acoustic driven drug delivery systems | UNIVERSITY OF OTAGO (NZ) | 2025-06-17 | — | — | US | disclosed |
| EP-4566632-A1 | MSLN ANTIBODY-DRUG CONJUGATE | Nona Biosciences (Suzhou) Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| EP-4556026-A1 | ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| WO-2023091706-A2 | METHODS FOR INTRATUMORAL DELIVERY OF CRISPR/CAS SYSTEMS | CHRISTIANA CARE GENE EDITING INSTITUTE, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| CN-116075321-A | Conjugates of FL118 drug and acid-sensitive linker and immunoconjugates using the same | 匹诺生物股份有限公司 | 2023-05-05 | — | — | CN | disclosed |
| WO-2023057814-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| EP-4103592-A1 | METHODS OF KILLING OR INHIBITING THE GROWTH OF CANCER CELLS | Tissuetech, Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-4097166-A1 | MICELLAR COMPOSITION FROM AN AMPHIPHILIC COPOLYMER FOR TUMOR THERAPY | Freie Universität Berlin (DE) | 2022-12-07 | — | — | EP | disclosed |
| CN-115443134-A | Conjugates of cell binding molecules and camptothecin analogs | 杭州多禧生物科技有限公司 | 2022-12-06 | — | — | CN | disclosed |
| US-11384104-B2 | Delivery systems for controlled drug release | CENTURION BIOPHARMA CORPORATION (US) | 2022-07-12 | — | — | US | disclosed |
| US-20220143182-A1 | ACOUSTIC DRIVEN DRUG DELIVERY SYSTEMS | UNIVERSITY OF OTAGO (NZ) | 2022-05-12 | — | — | US | disclosed |
| WO-2022094609-A1 | OLIGONUCLEOTIDE-BASED THERAPEUTICS AND USES THEREOF | SPEER TOD (US) | 2022-05-05 | — | — | WO | disclosed |
| US-11260126-B2 | Acoustic driven drug delivery systems | UNIVERSITY OF OTAGO (NZ) | 2022-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333541-A1 | ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF | TNFRSF9, F13B, FCGR1A | TOP1 1922/4885DDX5 3823/4885MEN1 1440/4885 |
| US-11384104-B2 | Delivery systems for controlled drug release | ABCB11, SLC10A1, SLC5A1 | TOP1 1182/4885DDX5 3471/4885MEN1 1969/4885 |
| US-12329815-B2 | Acoustic driven drug delivery systems | PARK7, NLN, OPA1 | TOP1 2843/4885DDX5 2895/4885MEN1 1634/4885 |
| US-20250375543-A1 | OLIGONUCLEOTIDE-BASED THERAPEUTICS AND USES THEREOF | POLRMT, DCLRE1B, POLM | TOP1 461/4885DDX5 297/4885MEN1 1707/4885 |
| US-20220143182-A1 | ACOUSTIC DRIVEN DRUG DELIVERY SYSTEMS | PARK7, NLN, OPA1 | TOP1 2843/4885DDX5 2895/4885MEN1 1634/4885 |
| US-11260126-B2 | Acoustic driven drug delivery systems | LSS, LIPA, MTREX | TOP1 1055/4885DDX5 813/4885MEN1 1174/4885 |
| US-20260102507-A1 | CAMPTOTHECIN DERIVATIVE FOR TREATING OR PREVENTING CANCER AND ANTIBODY-DRUG CONJUGATE THEREOF | MALT1, FCGRT, CHN2 | TOP1 6/4885DDX5 4835/4885MEN1 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.